Publications by authors named "C Busca"
Article Synopsis
- The study assessed the effects of hepatic steatosis-insulin resistance (HS-IR) and liver fibrosis (LF) on the development of type 2 diabetes mellitus (DM2) using specific measures (TyG and FIB-4).
- The incidence rates of DM2 were recorded as 12.9 per 1000 person-years for HS-IR and 9.8 per 1000 for LF.
- There was a significant reduction in the prevalence of HS-IR at both 12 and 24 months when treated with TDF combined with either 3TC or FTC and RPV, indicating beneficial treatment outcomes.
Liver fibrosis is a key determinant of the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Its increasing prevalence and a lack of effective treatments make it a major health problem worldwide, particularly in people living with HIV, among whom the prevalence of advanced fibrosis is higher. We have published preclinical data showing that Rilpivirine (RPV), a widely used anti-HIV drug, selectively triggers hepatic stellate cell (HSC) inactivation and apoptosis through signal transducer and activator of transcription (STAT)1-mediated pathways, effects that clearly attenuate liver fibrosis and promote regeneration.
View Article and Find Full Text PDFObjective: The incidence of type 2 diabetes mellitus (T2DM) has risen dramatically. Among people living with HIV (PLHIV), chronic disease (now >15 cases/1000 in the general population worldwide) and long-term exposure to antiretroviral therapy (ART) can alter metabolic processes early, favoring insulin resistance and T2DM. We retrospectively studied the incidence of T2DM and associated factors in the Cohort of the Spanish AIDS Research Network, a prospective cohort of PLHIV enrolled at diagnosis and before initiation of ART.
View Article and Find Full Text PDFBackground And Aims: We assessed long-term clinical outcomes and prognostic factors for liver disease progression after sustained viral response with direct-acting antivirals in patients coinfected with HIV/HCV with advanced fibrosis or cirrhosis.
Approach And Results: A total of 1300 patients who achieved sustained viral response with direct-acting antivirals from 2014 to 2017 in Spain were included: 1145 with compensated advanced chronic liver disease (384 advanced fibrosis and 761 compensated cirrhosis) and 155 with decompensated cirrhosis. The median follow-up was 40.
Background: Dolutegravir (DTG) plus lamivudine (3TC) has proven highly efficacious as a switching strategy in virologically suppressed people with HIV (PWH). As this strategy was introduced relatively recently, real-world, long-term durability studies are lacking.
Methods: We performed a retrospective review of treatment-experienced patients who started DTG + 3TC in a cohort of PWH.